Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402 Laura F. Newell, Todd E. Defor, Corey S. Cutler, Michael R. Verneris, Bruce R. Blazar, Joseph H. Antin, Alan Howard, Juan (Maggie) Wu, Margaret L. MacMillan, Angela Panoskaltsis-Mortari, Daniel J. Weisdorf, Shernan Holtan Biology of Blood and Marrow Transplantation Volume 23, Issue 3, Pages S73-S74 (March 2017) DOI: 10.1016/j.bbmt.2017.01.030 Copyright © 2016 Terms and Conditions
Figure 1 Adjusted Non-Relapse Mortality by Composite Score of log(sEng) + log(FS). Biology of Blood and Marrow Transplantation 2017 23, S73-S74DOI: (10.1016/j.bbmt.2017.01.030) Copyright © 2016 Terms and Conditions